Breast Cancer Diagnostics Market Development Status Highlighted for the Forecast Period 2027: GENERAL ELECTRIC COMPANY, Hologic, Koninklijke Philips, Micrima, Provista Diagnostics

Increasing prevalence of breast cancer along with advanced technology for its diagnosis is expected to fuel the growth of the breast cancer diagnosis market during the forecast period. Moreover, the introduction of new and better products by manufacturers is anticipated to offer growth opportunities to the companies in the market.

Breast cancer is the uncontrollable growth of tumour cells in the breasts. Generally, the cancer forms in either the lobules or the ducts of the breast. There are two types of breast cancers, invasive breast cancer and non-invasive breast cancer. During recent years, there has been an increase in the cases of breast cancer in women. Recently, breast cancer is also being detected in men. The American Cancer Society estimated that in 2015, more than 2,000 men would be diagnosed, and more than 400 men would die from the disease.

Breast Cancer Diagnostics Market to 2027 - Global Analysis and Forecasts by Screening Type (Laboratory Tests, Biopsy, Imaging, and Other Screening Types), Technology (Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), and Other Technologies), and Geography

Get Sample PDF Copy at https://www.theinsightpartners.com/sample/TIPRE00003015?OP+sK

Companies Featured are -
1. Abbott
2. F. Hoffmann-La Roche Ltd
3. Fujifilm Holdings Corporation
4. GENERAL ELECTRIC COMPANY
5. Hologic, Inc.
6. Koninklijke Philips N.V.
7. Micrima Limited
8. Provista Diagnostics, Inc.
9. Siemens Healthcare GmbH
10. Thermo Fisher Scientific Inc.

The "Global Breast Cancer Diagnosis Market Analysis to 2027" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by screening type, technology and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading breast cancer diagnosis market players and offers key trends and opportunities in the market.

North America is expected to contribute to the largest share in the breast cancer diagnosis market in the coming years, owing to rising prevalence of breast cancer cases in the region during the recent years. Asia Pacific is expected to witness significant growth in the market during the forecast period, due to rising investment of foreign players in developing economies such as, China and India.

The global breast cancer diagnosis market is segmented on the basis of screening type and technology. Based on screening type, the market is segmented as, laboratory tests, biopsy, imaging, and other screening types. On the basis of technology, the breast cancer diagnosis market is classified as, fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies.

Buy Complete Report at https://www.theinsightpartners.com/buy/TIPRE00003015?OP+sK

Contact us –
Phone : +1-646-491-9876
Email Id : sales@theinsightpartners.com
Website: https://www.theinsightpartners.com

About Us - The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

This release was published on openPR.